Phase 4 Epilepsy Trial, Recruiting NCT06967012 Sponsor: Affiliated Hospital of Nantong University Condition: Epilepsy
Back to Epilepsy

Phase 4 Epilepsy Trial, Recruiting

NCT06967012
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The patient and/or their legal guardian has agreed to take part and has signed a consent form.
  • Children aged 1 to 14 years old, of any gender.
  • People who have been diagnosed with a specific type of epilepsy involving focal seizures (seizures that start in one part of the brain) or seizures that start in one part of the brain and spread to both sides, based on recognised international medical guidelines.
  • People who have been taking one epilepsy medication at a stable dose for at least 4 weeks, and whose doctor considers it appropriate to add a medication called zonisamide to their treatment.
  • People who have had at least 2 seizures that spread to both sides of the brain per 28-day period during the 8 weeks before the study begins.

Who may not be able to join:

  • People who have previously been treated with zonisamide.
  • People with a known allergy to zonisamide, sulfonamide drugs, or any ingredients in the medication.
  • People with a history of drug or alcohol misuse.
  • People who have had thoughts of suicide or made a suicide attempt in the past 6 months.
  • People who are currently taking antidepressants, medications for anxiety, or antipsychotic medications.
  • People who have been diagnosed with a progressive disease that affects the brain and its function.
  • People whose seizures are not caused by epilepsy but by psychological causes (sometimes called non-epileptic seizures).
  • People diagnosed with severe lung disease, serious blood disorders, cancer, immune system conditions, or psychiatric illnesses.
  • People who have already had brain surgery for epilepsy, or who are planning to have epilepsy surgery within the next 4 months.
  • People whom the trial doctor considers unsuitable for participation for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 13962969655

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Affiliated Hospital of Nantong University
Registry
ClinicalTrials.gov
Start date
1 August 2024
Est. completion
31 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Primary Observational Indicators; Primary Observational Indicators

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov